JP2020504110A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020504110A5 JP2020504110A5 JP2019533396A JP2019533396A JP2020504110A5 JP 2020504110 A5 JP2020504110 A5 JP 2020504110A5 JP 2019533396 A JP2019533396 A JP 2019533396A JP 2019533396 A JP2019533396 A JP 2019533396A JP 2020504110 A5 JP2020504110 A5 JP 2020504110A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- subject
- seq
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022115212A JP7500662B2 (ja) | 2016-12-23 | 2022-07-20 | 抗第ＸＩ／ＸＩａ因子抗体による処置法 |
| JP2024091065A JP2024116221A (ja) | 2016-12-23 | 2024-06-05 | 抗第ＸＩ／ＸＩａ因子抗体による処置法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662438654P | 2016-12-23 | 2016-12-23 | |
| US62/438,654 | 2016-12-23 | ||
| US201762589851P | 2017-11-22 | 2017-11-22 | |
| US62/589,851 | 2017-11-22 | ||
| PCT/IB2017/058345 WO2018116267A2 (en) | 2016-12-23 | 2017-12-22 | Methods of treatment with anti-factor xi/xia antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022115212A Division JP7500662B2 (ja) | 2016-12-23 | 2022-07-20 | 抗第ＸＩ／ＸＩａ因子抗体による処置法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020504110A JP2020504110A (ja) | 2020-02-06 |
| JP2020504110A5 true JP2020504110A5 (https=) | 2021-04-30 |
| JP7110199B2 JP7110199B2 (ja) | 2022-08-01 |
Family
ID=61022382
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533396A Active JP7110199B2 (ja) | 2016-12-23 | 2017-12-22 | 抗第ＸＩ／ＸＩａ因子抗体による処置法 |
| JP2022115212A Active JP7500662B2 (ja) | 2016-12-23 | 2022-07-20 | 抗第ＸＩ／ＸＩａ因子抗体による処置法 |
| JP2024091065A Pending JP2024116221A (ja) | 2016-12-23 | 2024-06-05 | 抗第ＸＩ／ＸＩａ因子抗体による処置法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022115212A Active JP7500662B2 (ja) | 2016-12-23 | 2022-07-20 | 抗第ＸＩ／ＸＩａ因子抗体による処置法 |
| JP2024091065A Pending JP2024116221A (ja) | 2016-12-23 | 2024-06-05 | 抗第ＸＩ／ＸＩａ因子抗体による処置法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20200231701A1 (https=) |
| EP (1) | EP3558370A2 (https=) |
| JP (3) | JP7110199B2 (https=) |
| KR (3) | KR102702288B1 (https=) |
| CN (2) | CN110325211A (https=) |
| AU (2) | AU2017383537B2 (https=) |
| CA (1) | CA3048157A1 (https=) |
| IL (2) | IL267519B2 (https=) |
| WO (1) | WO2018116267A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6799530B2 (ja) | 2014-10-01 | 2020-12-16 | メディミューン リミテッド | チカグレロルに対する抗体および使用方法 |
| UY36751A (es) | 2015-06-26 | 2017-01-31 | Novartis Ag | Anticuerpos de factor xi y métodos de uso |
| TW201802121A (zh) | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
| IL267519B2 (en) * | 2016-12-23 | 2025-04-01 | Novartis Ag | Factor XI/XIA for use in the prevention, treatment, management, or reduction of the risk of stroke or thromboembolism in a patient with end-stage renal disease |
| AU2017383232B2 (en) | 2016-12-23 | 2024-09-12 | Novartis Ag | Factor XI antibodies and methods of use |
| KR102880762B1 (ko) | 2018-09-20 | 2025-11-03 | 에스에프제이 파마 엑스, 인코포레이티드 | 티카그렐러 활성을 반전시키는 방법 |
| KR20210151774A (ko) | 2019-04-16 | 2021-12-14 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | 항-FXI/FXIa 항체 및 그 용도 |
| CN110423278B (zh) * | 2019-08-08 | 2020-07-17 | 上海博槿生物科技有限公司 | 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用 |
| US20230071973A1 (en) * | 2019-12-20 | 2023-03-09 | Anthos Therapeutics, Inc. | Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies |
| EP4177274A4 (en) * | 2020-07-02 | 2024-04-03 | Beijing Tuo Jie Biopharmaceutical Co. Ltd. | Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof |
| TW202405022A (zh) * | 2022-06-24 | 2024-02-01 | 美商安瑟斯治療公司 | 與抗因子ｘｉ／因子ｘｉａ抗體之組合療法 |
| WO2025201156A1 (zh) * | 2024-03-28 | 2025-10-02 | 施能康生物医药（苏州）有限公司 | 靶向凝血因子xi的核酸及其用途 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| WO1992010591A1 (en) | 1990-12-14 | 1992-06-25 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| EP0571613B1 (en) | 1991-12-13 | 2003-09-17 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| HUT76369A (en) | 1994-07-29 | 1997-08-28 | Smithkline Beecham Corp | Novel soluble protein compounds |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US20070190059A1 (en) * | 1996-01-17 | 2007-08-16 | Smithkline Beecham Corporation | Antithrombotic agents |
| US20030235587A1 (en) * | 1998-08-07 | 2003-12-25 | Feuerstein Giora Z. | Anticoagulant agents useful in treatment of thrombosis |
| MA24512A1 (fr) * | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| WO2000007626A1 (en) * | 1998-08-07 | 2000-02-17 | Smithkline Beecham Corporation | Use of anti-coagulation factor antibodies as long-lasting protective agents |
| US6624295B1 (en) * | 1998-08-28 | 2003-09-23 | Genentech, Inc. | Human anti-factor IX/IXa antibodies |
| EP2213743A1 (en) | 2000-04-12 | 2010-08-04 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| KR20070116192A (ko) * | 2000-05-15 | 2007-12-06 | 스미스클라인 비참 코포레이션 | 항혈전제 |
| JP2011504371A (ja) * | 2007-11-21 | 2011-02-10 | オレゴン ヘルス アンド サイエンス ユニバーシティー | 抗第ｘｉ因子モノクローナル抗体およびその使用方法 |
| TR201820051T4 (tr) * | 2008-06-19 | 2019-01-21 | Prothix Bv | Anti-faktör XI Antikorlarının Trombüs Oluşumunun Engellenmesi Veya Tedavisi İçin Kullanılması |
| PT2373691T (pt) * | 2008-12-18 | 2019-05-08 | Univ Vanderbilt | Anticorpos anti-fxi e métodos de utilização |
| IL212911A0 (en) * | 2011-05-16 | 2011-07-31 | Omrix Biopharmaceuticals Ltd | Immunoglobulin reduced in thrombogenic contaminants and preparation thereof |
| EP2847228B1 (en) * | 2012-05-10 | 2018-07-25 | Bayer Pharma Aktiengesellschaft | Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof |
| UY36751A (es) * | 2015-06-26 | 2017-01-31 | Novartis Ag | Anticuerpos de factor xi y métodos de uso |
| IL267519B2 (en) * | 2016-12-23 | 2025-04-01 | Novartis Ag | Factor XI/XIA for use in the prevention, treatment, management, or reduction of the risk of stroke or thromboembolism in a patient with end-stage renal disease |
-
2017
- 2017-12-22 IL IL267519A patent/IL267519B2/en unknown
- 2017-12-22 IL IL316673A patent/IL316673A/en unknown
- 2017-12-22 EP EP17832998.3A patent/EP3558370A2/en active Pending
- 2017-12-22 KR KR1020197021024A patent/KR102702288B1/ko active Active
- 2017-12-22 KR KR1020267002235A patent/KR20260023597A/ko active Pending
- 2017-12-22 US US16/472,641 patent/US20200231701A1/en not_active Abandoned
- 2017-12-22 JP JP2019533396A patent/JP7110199B2/ja active Active
- 2017-12-22 AU AU2017383537A patent/AU2017383537B2/en active Active
- 2017-12-22 CN CN201780087088.7A patent/CN110325211A/zh active Pending
- 2017-12-22 WO PCT/IB2017/058345 patent/WO2018116267A2/en not_active Ceased
- 2017-12-22 CA CA3048157A patent/CA3048157A1/en active Pending
- 2017-12-22 CN CN202410462229.0A patent/CN118320078A/zh active Pending
- 2017-12-22 KR KR1020247029148A patent/KR102918597B1/ko active Active
-
2022
- 2022-02-11 US US17/670,270 patent/US20230002507A1/en not_active Abandoned
- 2022-07-20 JP JP2022115212A patent/JP7500662B2/ja active Active
-
2024
- 2024-06-05 JP JP2024091065A patent/JP2024116221A/ja active Pending
- 2024-07-23 US US18/781,421 patent/US20250197522A1/en active Pending
- 2024-12-23 AU AU2024287181A patent/AU2024287181A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020504110A5 (https=) | ||
| JP2017506626A5 (https=) | ||
| RU2013149792A (ru) | Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента | |
| JP2019513726A5 (https=) | ||
| JP2017537105A5 (https=) | ||
| PT1949915E (pt) | Método e sistema para remover rfnt1,rfnt2, e ril2 solúveis em pacientes | |
| JP2021526534A5 (https=) | ||
| RU2014106652A (ru) | Ингибирующие моноклональные антитела против фактора xii/xiia и их применения | |
| JP2018523684A5 (https=) | ||
| JP2020513757A5 (https=) | ||
| JP2016537380A5 (https=) | ||
| JP2023533030A5 (https=) | ||
| JP2023002547A (ja) | 慢性腎疾患の治療のためのデュラグルチド | |
| JP2022501368A5 (https=) | ||
| US20250075007A1 (en) | Treatment of Al Amyloidosis with the Combination of Monoclonal Antibodies Agains Immunoglobulin Light Chains and the CD38 Cell Membrane Molecule on Antibody-Producing And Other Immune Cells | |
| Ikegami et al. | Feasible usage of ABO incompatible grafts in living donor liver transplantation | |
| IL323497A (en) | Methods for treating eosinophilic gastroenteritis by administering an IL-4R antagonist | |
| US20020094332A1 (en) | Method of prophylaxis against large myocardial infractions | |
| EP3345924A1 (en) | Use of cd47 antibodies | |
| PT1737490E (pt) | Processos de tratamento da aterosclerose | |
| WO2021213523A1 (zh) | 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途 | |
| Biswas et al. | A retrospective study on patients of Guillain-Barre syndrome treated with therapeutic plasma exchange at a tertiary care hospital in Western Maharashtra | |
| CA2473786A1 (en) | Method of prophylaxis against large myocardial infarctions | |
| Bujnowska et al. | Outcomes of prolonged treatment with intravenous immunoglobulin infusions for acute antibody-mediated rejection in kidney transplant recipients | |
| WO2025130748A1 (zh) | 一种抗凝血因子XI/XIa抗体制剂 |